uniQure NV
UQ1
Company Profile
Business description
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
Contact
Paasheuvelweg 25
AmsterdamNH1105 BP
NLDT: +31 202406000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
221
Stocks News & Analysis
stocks
The ASX player evolving into a defensive haven
A well-timed simplification journey as boring evolves back in vogue.
stocks
12 picks for an income portfolio - Q1 2026 update
Passive income growth continues to exceed my target.
stocks
Strong guidance from undervalued ASX share
Shares surged after the announcement of first half fiscal 2026 guidance.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,174.10 | 12.00 | 0.13% |
| CAC 40 | 8,331.05 | 94.08 | -1.12% |
| DAX 40 | 24,417.80 | 284.44 | -1.15% |
| Dow JONES (US) | 49,387.34 | 60.09 | -0.12% |
| FTSE 100 | 10,609.08 | 58.55 | -0.55% |
| HKSE | 26,361.07 | 200.74 | 0.77% |
| NASDAQ | 24,378.14 | 90.34 | -0.37% |
| Nikkei 225 | 58,824.89 | 348.99 | 0.60% |
| NZX 50 Index | 12,915.45 | 9.78 | 0.08% |
| S&P 500 | 7,101.27 | 24.79 | -0.35% |
| S&P/ASX 200 | 8,953.30 | 13.60 | 0.15% |
| SSE Composite Index | 4,082.13 | 30.70 | 0.76% |